Member Info for marquisdesalade

Be careful what you wish for, what a stinker ;-)

The acquisition opportunities are there...

https://www.upstreamonline.com/lng/tellurian-explores-sale-of-upstream-business/2-1-1594542

Hahaha its the way he tells 'em

With mining operations ceased & power supply cut due to the avalanche, cashflow will be effectively frozen for whatever period we dont yet know. CNG needs to find $20m from somewhere to repay that 3 month bridge finance in April or else they will be in default, outlook looks decidedly dodgy

Revenues ramping up to £4m

Biotechnology company, Oxford BioDynamics (AIM:OBD), is poised for successful commercialization of its precision medicine tests for oncology.

https://investorsprism.com/oxford-biodynamics-a-winning-trifecta-of-technology-story-and-strong-management/#more-802483

Thanks Heartshares, so a $3,500 efficacy test representing 2% in relation to an average $190,000 treatment plan could well capture the market. From previous OBD rns' below, the eligible target market would appear to be 40% of 16.6m (6,640,000x $3,500) - even at a 1% uptake thats 66,400 x $3,500 = £232.4m USA revenues - Wow if the numbers are right!

...An estimated 16.6M people were living with cancer in the US in 2019. And it is estimated that there will be 1.9M new cancer cases in 2022 . Across the 15 indications for which immune checkpoint inhibitors have been approved as the first line (1L) or the second line (2L) of treatment, approximately 40% of all patients are eligible for ICI therapy...
Despite their potential efficacy, it has been estimated that ICIs are ineffective for up to 70% of patients treated, and these ineffective therapies in the US alone could add over 42% to annual spend. Currently, there are no predictive tools that accurately report the expected efficacy in individual patients.....
the high prices of ICIs, e.g. Keytruda costs approximately $190,000 in the US. It is estimated that annual savings to the US healthcare system through the personalised administration of ICIs following accurate prognosis could amount to as much as $10B+....

Anyone know the test pricing in UK/USA? I cant find any reference to it anywhere.

and a 165,000 sell at 18.05p but the bid is holding firm

https://meetings.asco.org/abstracts-presentations/212623

Why does this even remain listed? It cant capital raise on the market & has £12m outstanding debt to the chairman & vulpes

https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-eyes-potential-acquisitions-stat-news-2022-01-13/?rpc=401&

Jan 13 (Reuters) - Biogen Inc (BIIB.O) is working with investment bank Goldman Sachs (GS.N) to find potential targets for acquisitions, Stat News reported on Thursday, citing an unnamed source.

The report said the company's board had warmed to the idea of acquisitions amid the turmoil surrounding its controversial Alzheimer's drug Aduhelm

A well regarded contributor on the afn site has revealed that a very big player has taken a long position in prm, others are piling in on the back of it

prm just chugs along and barely washes its face on the current income streams which is heavily reliant on thermo/tmt

they need to announce something NEW!

He seems to be busy buying shares in Scancell these days, £25k worth yesterday

No one has any idea what prm are up to because of their continued silence, shareholder/market communications are non existant

The Sohngens incorporated Paion HQ in Aachen & the ceo was the chief medical officer, with her close links to Humanwell BV & the proximity of the Frankfurt lab surely theres an open goal for prm to at least provide testing services for phase 3 trials

PAION ANNOUNCES PROGRESS WITH REMIMAZOLAM BY ITS PARTNER YICHANG HUMANWELL IN CHINA
- Recent launch of Ruima(R) (remimazolam) in procedural sedation

- Yichang Humanwell has started a Phase III trial in general anesthesia

Aachen (Germany), 11 August 2020 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces that its Chinese remimazolam licensee Yichang Humanwell has recently launched Ruima(R) (remimazolam) in procedural sedation in China. In addition, a Phase III trial in general anesthesia in China has started patient recruitment. The Phase III study is a multicentre, single-blind randomized comparative clinical trial of efficacy and safety of remimazolam versus propofol in induction and maintenance of general anesthesia in 516 elective surgery patients.

Remimazolam (brand name Ruima(R)) was approved in China for procedural sedation in July 2020.

I'm still wondering why has she taken the prm ceo job, if not with a mandate to sell it.

Soehngen, has been mandated by YHW to found and manage YHW´s European subsidiary to be established in H1 2020 as co-CEOs

https://troutaccess.com/investor.php/participatingcompanies/details/company_hash/8ae3c4b878c5c67f2a0fdf6e42a838c7/conference_hash/9cb784a9d56b966d048414948796f653

The Soehngens are excited to work together - again - as the designated Co-CEOs of Humanwell Pharmaceuticals Europe B.V. in foundation

https://de.linkedin.com/in/wolfgang-s%C3%B6hngen-60b2951

Has this new CEO been appointed to broker a sale of prm? Surely pearce & vulpes must be looking at an exit by now. Looking at her cv profile she doesnt hang about for long, and what about her recent links to the chinese biotech in particular incorporating a BV European subsidiary? Might explain the silence on all fronts?

what a strange company this is, you'd think a listed plc would try to generate some interest in its shares but theres never any news. 2020 has been biotechs year but its passed prm by.